指南与共识产科母胎医学

产科麻醉与围产医学会、母胎医学会与美国区域麻醉和疼痛医学会关于阿片类药物使用障碍孕妇疼痛管理的共识声明

Consensus statement on pain management for pregnant patients with opioid use disorder from the Society for Obstetric Anesthesia and Perinatology, Society for Maternal-Fetal Medicine, and American Society of Regional Anesthesia and Pain Medicine.
指南 / 共识 · Am J Obstet Gynecol · 2025-03-11

该多学科共识声明由产科麻醉与围产医学会、母胎医学会与美国区域麻醉和疼痛医学会联合制定,为产科阿片类药物使用障碍患者的疼痛管理提供框架,涵盖产前疼痛管理优化、分娩镇痛及阴道分娩后和剖宫产后的疼痛管理,包括非药物与药物选择、阿片类药物使用障碍的药物管理(如丁丙诺啡、美沙酮)、尿液药物检测及母婴二元社会因素等,提供循证推荐以优化疼痛管理并降低围产期风险。

要点

  • 多学科共识声明为产科阿片类药物使用障碍患者提供疼痛管理框架。
  • 内容涵盖产前优化、分娩镇痛、阴道分娩后及剖宫产后的疼痛管理。
  • 讨论非药物与药物选择、丁丙诺啡和美沙酮等药物管理及尿液药物检测。

核心结论

  • 该多学科共识声明提供实用且简明的临床指导,以优化妊娠期阿片类药物使用障碍患者的疼痛管理,改善母婴结局。

研究设计与样本

  • 由产科麻醉与围产医学会、母胎医学会与美国区域麻醉和疼痛医学会联合制定的多学科共识声明,目标读者为产科和麻醉科医疗提供者。

主要发现

  • 声明聚焦于产前疼痛管理优化、分娩镇痛与阴道分娩后疼痛管理以及剖宫产术后疼痛管理。
  • 主题包括非药物和药物疼痛管理选择、阿片类药物使用障碍的药物管理(如丁丙诺啡、美沙酮)、尿液药物检测及母婴二元社会因素。
  • 声明回顾了当前实践并提供循证推荐,以优化疼痛管理同时降低围产期阿片类药物使用障碍相关风险与并发症。

临床怎么用

  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pain management in pregnant and postpartum people with an opioid use disorder requires a balance among the risks associated with opioid tolerance, including withdrawal or return to opioid use, considerations around the social needs of the maternal-infant dyad, and the provision of adequate pain relief for the birth episode that is often characterized as the worst pain a person will experience in their lifetime. This multidisciplinary consensus statement from the Society for Obstetric Anesthesia and Perinatology, the Society for Maternal-Fetal Medicine, and the American Society of Regional Anesthesia and Pain Medicine provides a framework for pain management in obstetrical patients with opioid use disorder. The purpose of this consensus statement is to provide practical and evidence-based recommendations and is targeted to healthcare providers in obstetrics and anesthesiology. The statement is focused on prenatal optimization of pain management, labor analgesia and postvaginal delivery pain management, and postcesarean delivery pain management. Topics include a discussion of nonpharmacologic and pharmacologic options for pain management, medication management for opioid use disorder (eg, buprenorphine, methadone), considerations regarding urine drug testing and other social aspects of care for maternal-infant dyads, and a review of current practices. The authors provide evidence-based recommendations to optimize pain management while reducing risks and the complications associated with opioid use disorder in the peripartum period. Ultimately, this multidisciplinary consensus statement provides practical and concise clinical guidance to optimize pain management for people with opioid use disorder in the context of pregnancy to improve maternal and perinatal outcomes.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lim G, Carvalho B, George RB, et al. Consensus statement on pain management for pregnant patients with opioid use disorder from the Society for Obstetric Anesthesia and Perinatology, Society for Maternal-Fetal Medicine, and American Society of Regional Anesthesia and Pain Medicine. Am J Obstet Gynecol. 2025. PMID: 40074574. doi:10.1016/j.ajog.2024.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。